Domov › Nemalobunkový karcinóm pľúc › Florida › Deltona
Klinické štúdie Nemalobunkový karcinóm pľúc v meste Deltona, FL
15 štúdií pre Nemalobunkový karcinóm pľúc hľadá účastníkov v zariadeniach v meste Deltona a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Prebieha náborFáza 1/2
- Mid Florida Hematology And Oncology Center /ID# 273777, Orange City · 4 míľ odtiaľ
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Prebieha náborFáza 3
- Mid Florida Hematology and Oncology Center ( Site 0018), Orange City · 4 míľ odtiaľ
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Prebieha náborFáza 3
- Alpha Clinical Research Centers LLC, Orange City · 4 míľ odtiaľ
- Florida Cancer Specialists, Orange City · 4 míľ odtiaľ
- Mid Florida Hematology and Oncology Center, Orange City · 4 míľ odtiaľ
- a 1 ďalších
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Prebieha náborFáza 3
- Mid Florida Hematology and Oncology Center, Orange City · 4 míľ odtiaľ
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Prebieha náborFáza 1/2
- Mid Florida Hematology and Oncology Center, Orange City · 4 míľ odtiaľ
Pan-tumor MRD Study
Prebieha náborObservačná štúdia
- Mid Florida Cancer Centers, Orange City · 4 míľ odtiaľ
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Prebieha náborFáza 3
- Research Site, Orange City · 4 míľ odtiaľ
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Prebieha náborFáza 3
- Mid Florida Hematology and Oncology Center, Orange City · 4 míľ odtiaľ
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Prebieha náborFáza 2/3
- Mid Florida Cancer Centers, Orange City · 4 míľ odtiaľ
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Prebieha náborFáza 3
- Mid Florida Hematology and Oncology Center, Orange City · 4 míľ odtiaľ
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Prebieha náborFáza 2/3
- Local Institution - 007-926-B, Daytona Beach · 26 míľ odtiaľ
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Prebieha náborFáza 3
- Mid-Florida Hematology & Oncology Centers, P.A., Orange City · 4 míľ odtiaľ
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Prebieha náborFáza 3
- Research Site, Orange City · 4 míľ odtiaľ
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Prebieha náborFáza 1/2
- Mid Florida Hematology and Oncology Center, Orange City · 4 míľ odtiaľ
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Prebieha náborFáza 2
- Mid Florida Hematology and Oncology Center, Orange City · 4 míľ odtiaľ
Štúdie Nemalobunkový karcinóm pľúc v iných mestách
- Houston, TX145 štúdií
- New York City, NY121 štúdií
- Arlington, VA104 štúdií
- Nashville, TN97 štúdií
- Boston, MA90 štúdií
- Los Angeles, CA87 štúdií
- St. Louis, MO73 štúdií
- Chicago, IL61 štúdií
- Baltimore, MD60 štúdií
- San Antonio, TX59 štúdií
- Columbus, OH57 štúdií
- Washington, DC55 štúdií
Iné štúdie v Deltona
- Obézita11 štúdií
- Alzheimerova choroba10 štúdií
- Diabetes mellitus 2. typu10 štúdií
- Nadváha9 štúdií
- Rakovina prsníka8 štúdií
- Rakovina pľúc8 štúdií
- Rakovina (všetky typy)7 štúdií
- Metastatická rakovina5 štúdií
- CHOPN5 štúdií
- Vysoký krvný tlak5 štúdií
- Melanóm5 štúdií
- Osteoartritída kolena5 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.